Search
Plus Therapeutics Inc
PSTVAdd to Watchlist
5.250USD
-0.510-8.85%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
36.03MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-8.85%
5 Days
-14.22%
1 Month
-11.76%
6 Months
-58.94%
Year to Date
-59.01%
1 Year
-50.00%
TradingKey Stock Score of Plus Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Plus Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Plus Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Plus Therapeutics Inc Highlights
StrengthsRisks
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.21M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.21M.
Undervalued
The company’s latest PE is -1.52, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.08M shares, increasing 43.32% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 99.37K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
38.000
Target Price
+559.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Plus Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Plus Therapeutics Inc Info
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Ticker SymbolPSTV
CompanyPlus Therapeutics Inc
CEOHedrick (Marc H)
Websitehttp://www.plustherapeutics.com/
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78135.170
-95.830 (-0.12%)
422.240
-21.060 (-4.75%)
